CLINICAL TRIALS PROFILE FOR MYCIFRADIN

All Clinical Trials for MYCIFRADIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00945334 ↗	Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome	Completed	Bausch Health Americas, Inc.	N/A	2009-08-01	In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.
NCT00945334 ↗	Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome	Completed	Valeant Pharmaceuticals International, Inc.	N/A	2009-08-01	In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.
NCT00945334 ↗	Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome	Completed	Mark Pimentel, MD	N/A	2009-08-01	In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.
NCT03557008 ↗	Systems Biology of Inactivated Rabies Vaccine in Healthy Adults With or Without Use of Broad Spectrum Antibiotics	Active, not recruiting	Emory University	Phase 4	2018-07-05	The study is a prospective randomized, unblinded study looking to enroll 54 subjects at Emory University. The use of antibiotics changes micro-organisms in the intestines. The change to micro-organisms in the intestines may change the body's vaccine immune response and alter the effectiveness of the rabies vaccine. There will be two randomized groups (1:1 randomization). Group A will start taking an antibiotic regimen by mouth 3 days prior to vaccination and continue taking antibiotics the day of rabies vaccination and one day after vaccination for a total of 5 days. Group B will only receive the rabies vaccination and will not take any antibiotics. The dosage of each antibiotic is taken from their respective package inserts and does not exceed the maximum dose allowed for each antibiotic. The purpose of the study is to look at certain markers (immune responses) in blood and lymph nodes after rabies vaccination with or without the use of antibiotics from day of vaccination to 28 days post vaccination in both groups.

Clinical Trial Conditions for MYCIFRADIN

Condition Name

Condition Name for MYCIFRADIN
Intervention	Trials
Constipation-predominant Irritable Bowel Syndrome	1
Rabies Human	1

Condition MeSH

Condition MeSH for MYCIFRADIN
Intervention	Trials
Rabies	1
Syndrome	1
Irritable Bowel Syndrome	1
Constipation	1

Clinical Trial Locations for MYCIFRADIN

Trials by Country

Trials by Country for MYCIFRADIN
Location	Trials
United States	3

Trials by US State

Trials by US State for MYCIFRADIN
Location	Trials
Georgia	2
California	1

Clinical Trial Progress for MYCIFRADIN

Clinical Trial Phase

Clinical Trial Phase for MYCIFRADIN
Clinical Trial Phase	Trials
Phase 4	1
N/A	1

Clinical Trial Status

Clinical Trial Status for MYCIFRADIN
Clinical Trial Phase	Trials
Active, not recruiting	1
Completed	1

Clinical Trial Sponsors for MYCIFRADIN

Sponsor Name

Sponsor Name for MYCIFRADIN
Sponsor	Trials
Valeant Pharmaceuticals International, Inc.	1
Mark Pimentel, MD	1
Emory University	1

Sponsor Type

Sponsor Type for MYCIFRADIN
Sponsor	Trials
Other	2
Industry	2

Last updated: July 4, 2026

MYCIFRADIN clinical trials update and market projection: what’s in the pipeline, who’s running studies, and when peak sales could arrive

MYCIFRADIN is a proprietary drug name used in clinical development, but no reliable public record was provided that identifies the active ingredient, therapeutic indication, sponsor, trial identifiers, or FDA/regulatory status. Without those linkable facts, a complete, accurate clinical-trials update, market sizing, and timeline-to-peak projection cannot be produced.

What clinical trials are testing MYCIFRADIN right now?

Answer: No verifiable, source-backed trial identifiers or sponsor/indication details are available for MYCIFRADIN from the information provided.

Are there Phase 1, Phase 2, Phase 3 MYCIFRADIN trials?

Answer: Not determinable. A clinical-trials update requires at minimum NCT/EudraCT/ISRCTN identifiers, indication, and sponsor.

Which endpoints does MYCIFRADIN use in ongoing studies?

Answer: Not determinable. Endpoint specifics require trial protocol or results postings.

Who is sponsoring and recruiting MYCIFRADIN clinical trials?

Answer: Not determinable. Sponsor identity, trial sites, and recruitment status cannot be verified.

Where are MYCIFRADIN trials being conducted geographically?

Answer: Not determinable. Geography requires trial registries or press releases tied to a specific active ingredient and study record.

What is the regulatory status of MYCIFRADIN with the FDA or EMA?

Answer: Not determinable. Regulatory status requires a specific INN/USAN name or an application reference, plus Orange Book/Drug Trials Snapshots/EMA pages.

Is MYCIFRADIN in any FDA pathway (Fast Track, Breakthrough, Priority Review)?

Answer: Not determinable.

Has MYCIFRADIN received any approval, refusal, or CRL from regulators?

Answer: Not determinable.

What markets could MYCIFRADIN enter and how big are those indications?

Answer: Not determinable. Indication and approved label scope are required for market sizing.

What patient populations would be targeted by MYCIFRADIN?

Answer: Not determinable without disease/line-of-therapy and inclusion criteria.

What comparators would MYCIFRADIN face on launch?

Answer: Not determinable without indication and mechanism-of-action.

What is the sales projection for MYCIFRADIN (base case, bull case, bear case)?

Answer: Not determinable. Peak sales modeling requires: indication, dosing regimen, expected efficacy relative to standard of care, safety profile, pricing assumptions, penetration curve, geography, and forecast horizon.

How would MYCIFRADIN pricing and reimbursement shape revenue?

Answer: Not determinable.

What share could MYCIFRADIN win versus incumbents and generics/biosimilars?

Answer: Not determinable.

When could MYCIFRADIN reach peak sales, and what timelines drive the forecast?

Answer: Not determinable. Timing requires a development timeline (Phase 1 to Phase 3 completion dates, NDA/BLA submission, PDUFA/CHMP decisions) and trial outcome probabilities.

What generic or biosimilar entry risks exist for MYCIFRADIN?

Answer: Not determinable. Entry risk depends on patent estate status, composition-of-matter, exclusivity, and whether MYCIFRADIN is small molecule or biologic.

Does MYCIFRADIN have Orange Book-listed patents or Hatch-Waxman exclusivity?

Answer: Not determinable. Orange Book requires an FDA product/active ingredient mapping.

If MYCIFRADIN is a biologic, does it face biosimilar competition timelines?

Answer: Not determinable.

What patent estate issues could affect MYCIFRADIN commercialization?

Answer: Not determinable. Patent analysis requires the active ingredient, assignees, and listed filings.

MYCIFRADIN competitive landscape: how does it compare with current standard of care?

Answer: Not determinable. Comparison requires mechanism, trial populations, and efficacy/safety results.

What are the biggest go-to-market risks for MYCIFRADIN?

Answer: Not determinable. Risks depend on: late-stage readouts, label breadth, safety signals, manufacturing scale, payer adoption, and differentiation.

Manufacturing and supply chain risks

Answer: Not determinable.

Safety and tolerability risks

Answer: Not determinable.

Clinical differentiation risks

Answer: Not determinable.

Key Takeaways

• A complete clinical-trials update and market projection for MYCIFRADIN cannot be generated because the provided information does not identify the drug’s active ingredient, indication, sponsor, trial identifiers, or regulatory record.
• Any attempt to estimate trials, timelines, exclusivity, competitive positioning, or revenues without those linkable facts would not be accurate.

FAQs

1. How can investors verify MYCIFRADIN trial activity without NCT numbers?
2. What indicators signal that MYCIFRADIN has entered Phase 3?
3. How do you map a proprietary name like MYCIFRADIN to an INN for Orange Book checks?
4. What inputs are required for peak sales modeling in oncology versus chronic disease?
5. How do settlement agreements affect generic entry timing when patents are involved?

References

(No sources were cited because no verifiable MYCIFRADIN-specific clinical, regulatory, or commercial data was provided.)